Castle Biosciences (CSTL) Aperçu de l'action
Castle Biosciences, Inc. est une société de diagnostic moléculaire qui propose des solutions de test pour le diagnostic et le traitement des cancers dermatologiques, de l'œsophage de Barrett (BE), de la dermatite atopique (DA) et du mélanome uvéal. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
CSTL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Castle Biosciences, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$20.15 |
| Plus haut sur 52 semaines | US$44.28 |
| Plus bas sur 52 semaines | US$14.59 |
| Bêta | 1.11 |
| Variation sur 1 mois | -19.72% |
| Variation sur 3 mois | -31.02% |
| Variation sur 1 an | 25.16% |
| Variation sur 3 ans | -22.50% |
| Variation sur 5 ans | -66.38% |
| Évolution depuis l'introduction en bourse | -5.84% |
Nouvelles et mises à jour récentes
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Recent updates
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Summary Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market. I assign CSTL a conviction rating of 3/5, initiating a pilot position near technical support, with plans to build exposure as the market digests 2026 earnings and product adoption. Read the full article on Seeking AlphaCSTL: Preliminary 2025 Revenue Signals Stronger Confidence In 2026 Outlook
Analysts have lifted their price targets on Castle Biosciences by amounts ranging up to $17, pointing to updated revenue estimates through 2026 and recent preliminary 2025 revenue disclosures as key drivers of their revised outlooks. Analyst Commentary Recent research notes focus on how preliminary 2025 revenue disclosures and updated 2026 revenue estimates feed into Castle Biosciences' valuation, with several firms adjusting their price targets to reflect these updated assumptions.CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have modestly adjusted their fair value estimate for Castle Biosciences to $48.50, citing updated revenue growth and profit margin assumptions, as well as a slightly lower future P/E multiple, as reflected in recent price target increases from several firms. Analyst Commentary Recent research updates on Castle Biosciences have centered on revised revenue assumptions for 2025 and beyond, along with higher price targets that feed into the updated fair value estimate of $48.50.CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have raised their average price target on Castle Biosciences by $14, citing updated models that now rely more on 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent research updates on Castle Biosciences focus heavily on how preliminary 2025 revenue information feeds into 2026 models, which in turn support higher price targets.CSTL: Preliminary 2025 Revenue Signals Will Support Extended 2026 Upside Potential
Narrative Update The updated analyst price target for Castle Biosciences moves from $46.00 to about $48.57. Analysts point to refreshed assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change.CSTL: Extended 2026 Revenue View And Test Adoption Will Support Upside
Narrative Update: Castle Biosciences Analysts have lifted their fair value estimate for Castle Biosciences from US$42.50 to US$46.00, citing updated modeling that now anchors price targets on 2026 revenue expectations following preliminary 2025 revenue disclosures. Analyst Commentary Recent Street commentary around Castle Biosciences is centering on how the preliminary 2025 revenue update reshapes expectations and valuation anchors out to 2026.CSTL: Dermatology Test Adoption And New Launches Will Support Balanced Outlook
Analysts have lifted their price target on Castle Biosciences from US$38.75 to US$42.50, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News New data from a prospective multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM and PRAME for uveal melanoma outcomes was published in Nature Communications, with DecisionDx-UM described as widely adopted in the U.S. standard of care and included in AJCC and NCCN guidelines (Key Developments).CSTL: Broader Dermatology Test Adoption Will Support Balanced Long-Term Outlook
Analysts have raised their price target on Castle Biosciences to approximately 38.75 dollars from about 35.63 dollars, citing stronger expectations for revenue growth and slightly improved profit margins, despite a modestly higher discount rate and lower projected future P E multiple. What's in the News An independent expert consensus panel endorsed Castle Biosciences DecisionDx-Melanoma test as providing robust, clinically validated prognostic information that improves melanoma risk stratification and supports more precise treatment decisions (expert consensus paper).Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up
Despite an already strong run, Castle Biosciences, Inc. ( NASDAQ:CSTL ) shares have been powering on, with a gain of...What Castle Biosciences, Inc.'s (NASDAQ:CSTL) 30% Share Price Gain Is Not Telling You
The Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has done very well over the last month, posting an excellent...Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
Unfortunately for some shareholders, the Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has dived 28% in the last...When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
While Castle Biosciences, Inc. ( NASDAQ:CSTL ) might not have the largest market cap around , it saw a double-digit...Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Summary Castle Biosciences offers diverse diagnostic tests, with DecisionDx-Melanoma being a key revenue driver, but faces potential Medicare reimbursement loss for DecisionDx-SCC in 2025. The company is expanding its portfolio with TissueCypher and IDgenetix, showing strong growth, though IDgenetix faces uncertain long-term performance. Castle is well capitalized with $293 million in cash, providing a strong runway, but continues to burn cash, mainly on general and admin expenses. Trading near 52-week lows, CSTL stock presents a good entry point, but investors should watch for clarity on the SCC non-coverage issue. Read the full article on Seeking AlphaPinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Key Insights The projected fair value for Castle Biosciences is US$66.66 based on 2 Stage Free Cash Flow to Equity...Castle Biosciences: Inflection Into Profitability
Summary Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. Castle Biosciences faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field. Read the full article on Seeking AlphaUpgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Celebrations may be in order for Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders, with the analysts delivering a...Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders of Castle Biosciences, Inc. ( NASDAQ:CSTL ) will be pleased this week, given that the stock price is up...Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders are no doubt pleased to see that the share price has bounced 28...Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Castle Biosciences, Inc.'s ( NASDAQ:CSTL ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...Rendement pour les actionnaires
| CSTL | US Healthcare | US Marché | |
|---|---|---|---|
| 7D | 5.3% | -0.4% | 1.0% |
| 1Y | 25.2% | 16.3% | 28.7% |
Rendement vs Industrie: CSTL a dépassé le secteur US Healthcare qui a rapporté 16.3 % au cours de l'année écoulée.
Rendement vs marché: CSTL a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 8.6% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: CSTL n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CSTL ( 9% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2007 | 942 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc. est une société de diagnostic moléculaire qui propose des solutions de test pour le diagnostic et le traitement des cancers dermatologiques, de l'œsophage de Barrett (BE), de la dermatite atopique (DA) et du mélanome uvéal. La société propose DecisionDx-Melanoma, un test de stratification du risque par profil d'expression génique (GEP) qui prédit la probabilité d'un ganglion lymphatique sentinelle positif et le risque de métastases pour les patients atteints de mélanome cutané invasif ; TissueCypher, un test spatialomique de stratification du risque pour prédire le développement futur d'une dysplasie de haut grade et/ou d'un cancer de l'œsophage chez les patients atteints de BE non dysplasique, de dysplasie indéfinie et de dysplasie de bas grade ; AdvanceAD-Tx, un test GEP non invasif conçu pour guider le choix du traitement systémique chez les patients âgés de 12 ans et plus atteints de la MA modérée à sévère ; DecisionDx-SCC, un test GEP pour le carcinome épidermoïde cutané ; et MyPath Melanoma, un test GEP diagnostique à utiliser chez les patients présentant des lésions mélanocytaires difficiles à diagnostiquer. Elle propose également DecisionDx-UM, un test GEP de stratification du risque qui prédit le risque de métastases pour les patients atteints de mélanome uvéal.
Castle Biosciences, Inc. Résumé des fondamentaux
| CSTL statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$622.98m |
| Bénéfices(TTM) | -US$12.83m |
| Recettes(TTM) | US$339.92m |
Le site CSTL est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CSTL compte de résultat (TTM) | |
|---|---|
| Recettes | US$339.92m |
| Coût des recettes | US$75.18m |
| Marge brute | US$264.74m |
| Autres dépenses | US$277.57m |
| Les revenus | -US$12.83m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.42 |
| Marge brute | 77.88% |
| Marge bénéficiaire nette | -3.78% |
| Ratio dettes/capitaux propres | 2.2% |
Quelles ont été les performances à long terme de CSTL?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 07:38 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Castle Biosciences, Inc. est couverte par 9 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |